top of page
TrippBio, Inc.
Login to favorite a company
TrippBio is developing a new, therapeutic application of an FDA-approved drug with a high probability to be proven safe and efficacious in the treatment and prevention of the SARS-CoV-2 virus that causes COVID-19.
Most Recent Valuation:
$5,255,840.00
Legal Name:
Founded:
State of HQ:
TrippBio, Inc
5/1/2020
FL
Company Description
Employees:
18
Funding Summary
Number of funding rounds
2
Total amount raised
$185,796
Round name | End date | Raised | Status | Type | Investment minimum | Valuation | Valuation Cap | Price per share |
|---|---|---|---|---|---|---|---|---|
TrippBio Common Stock 2 | null | open | Common Stock | $250 | $24,820,000 | 0.42 | ||
TrippBio, Inc. Stock 1 | 01/29/2021 | $185,796.00 | closed | Common Stock | $100 | $5,255,840 | 4 |
See round history
Round history
Round name | Perk description | Perk level (dollars) | Perk level (days) |
|---|
Loading...
Early Bird Perk history
Company notes
Type | Round name | Date Added | Date Updated | Notes |
|---|
Loading...
Financials (up to prior 4 years)
Revenue
COGS
Gross margin | (%)
Taxes
SG&A, other
Net income
Cash/Equivalents
Accounts Receiv
Other Assets
Assets
Short term debt
Long term debt
Equity/other liabilities
2019
0
0
0
na
0
0
0
0
0
0
0
0
0
0
2018
0
0
0
na
0
0
0
0
0
0
0
0
0
0
Gross margin, Other Assets, and Equity/other liabilities are derived from the financial statements of the company reported to the SEC. Assets = Liabilities + Equity, and no equity accounts nor accounts payable are reported to the SEC, hence the possibility for that amount to be either equity or a liability.
bottom of page